Cargando…
MON-361 Isolated ACTH Deficiency after Treatment with Immune-Checkpoint Inhibitors
Background: Immune-checkpoint inhibitors targeting PDI or CTLA-4 are promising therapies in metastatic malignancies, including metastatic melanoma, and their usage has been increasing over the last few years. As more patients are treated with these agents, there will likely be an increased incidence...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Endocrine Society
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6550779/ http://dx.doi.org/10.1210/js.2019-MON-361 |